Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:AOXG NASDAQ:DWTX OTCMKTS:IMUC NASDAQ:TLPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAOXGAoxing Pharmaceutical$0.01+1.5%$0.01$0.00▼$0.02$2.52M6.739,116 shs390 shsDWTXDogwood Therapeutics$4.76+5.8%$4.99$1.62▼$29.28$8.60M1.81.45 million shs22,941 shsIMUCEOM Pharmaceutical$0.08$0.09$0.01▼$0.21$9.78M-0.01783 shs77 shsTLPHTalphera$0.43$0.49$0.38▼$1.19$8.82M-0.11137,451 shs208,501 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAOXGAoxing Pharmaceutical+1.54%-12.00%-28.26%-17.50%-44.54%DWTXDogwood Therapeutics-4.26%-8.54%-6.05%+5.39%+449,999,900.00%IMUCEOM Pharmaceutical-0.01%+15.19%-26.25%-44.32%-54.27%TLPHTalphera-1.69%-14.68%-10.60%-10.60%-52.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAOXGAoxing PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/ADWTXDogwood Therapeutics1.7209 of 5 stars3.50.00.00.02.20.00.6IMUCEOM PharmaceuticalN/AN/AN/AN/AN/AN/AN/AN/ATLPHTalphera2.3851 of 5 stars3.82.00.00.03.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAOXGAoxing Pharmaceutical 0.00N/AN/AN/ADWTXDogwood Therapeutics 3.00Buy$10.00110.08% UpsideIMUCEOM Pharmaceutical 0.00N/AN/AN/ATLPHTalphera 3.50Strong Buy$5.001,062.79% UpsideCurrent Analyst Ratings BreakdownLatest AOXG, IMUC, TLPH, and DWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2025DWTXDogwood TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$10.00(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAOXGAoxing PharmaceuticalN/AN/AN/AN/AN/AN/ADWTXDogwood TherapeuticsN/AN/AN/AN/A($7.56) per shareN/AIMUCEOM PharmaceuticalN/AN/AN/AN/AN/AN/ATLPHTalphera$27K326.53N/AN/A$0.47 per share0.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAOXGAoxing PharmaceuticalN/AN/A0.00∞N/AN/AN/AN/AN/ADWTXDogwood Therapeutics-$12.35M-$18.04N/AN/AN/AN/AN/A-34.74%8/6/2025 (Estimated)IMUCEOM Pharmaceutical-$1.89MN/A0.00∞N/AN/AN/AN/AN/ATLPHTalphera-$13M-$0.45N/AN/AN/AN/A-130.28%-59.25%8/13/2025 (Estimated)Latest AOXG, IMUC, TLPH, and DWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025DWTXDogwood Therapeutics-$1.26N/AN/AN/AN/AN/A8/13/2025Q2 2025TLPHTalphera-$0.1150N/AN/AN/AN/AN/A5/8/2025Q1 2025DWTXDogwood Therapeutics-$0.77-$4.21-$3.44-$8.45N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAOXGAoxing PharmaceuticalN/AN/AN/AN/AN/ADWTXDogwood TherapeuticsN/AN/AN/AN/AN/AIMUCEOM PharmaceuticalN/AN/AN/AN/AN/ATLPHTalpheraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAOXGAoxing PharmaceuticalN/AN/AN/ADWTXDogwood TherapeuticsN/A7.437.43IMUCEOM PharmaceuticalN/AN/AN/ATLPHTalpheraN/A3.113.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAOXGAoxing PharmaceuticalN/ADWTXDogwood Therapeutics9.05%IMUCEOM PharmaceuticalN/ATLPHTalphera37.67%Insider OwnershipCompanyInsider OwnershipAOXGAoxing Pharmaceutical17.80%DWTXDogwood Therapeutics3.90%IMUCEOM Pharmaceutical3.28%TLPHTalphera3.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAOXGAoxing Pharmaceutical350381.21 million313.35 millionNot OptionableDWTXDogwood Therapeutics51.91 million1.84 millionN/AIMUCEOM Pharmaceutical3126.50 million122.35 millionNot OptionableTLPHTalphera1920.50 million19.85 millionOptionableAOXG, IMUC, TLPH, and DWTX HeadlinesRecent News About These Companiestalphera receives extension to meet nasdaq listing requirementsJune 7, 2025 | investing.comTalphera Granted Extension for Nasdaq ComplianceJune 5, 2025 | tipranks.comTalphera, Inc.: Talphera Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 17, 2025 | finanznachrichten.deEarnings call transcript: Talphera Inc. outlines strategic shifts in Q1 2025May 16, 2025 | uk.investing.comTalphera, Inc. (NASDAQ:TLPH) Q1 2025 Earnings Call TranscriptMay 16, 2025 | msn.comTalphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financingMay 15, 2025 | msn.comTalphera, Inc. (TLPH) Q1 2025 Earnings Call TranscriptMay 14, 2025 | seekingalpha.comTalphera Announces First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | prnewswire.comTalphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025May 7, 2025 | prnewswire.comAll You Need to Know About Talphera (TLPH) Rating Upgrade to Strong BuyMay 7, 2025 | msn.comTalphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock?April 5, 2025 | msn.comTalphera reports Q4 EPS (7c) vs. (25c) last yearApril 1, 2025 | markets.businessinsider.comTalphera, Inc. (NASDAQ:TLPH) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comTalphera announces agreement with FDA to reduce NEPHRO CRRT study sizeApril 1, 2025 | markets.businessinsider.comTalphera Reports 2024 Financial Results and Study UpdateMarch 31, 2025 | tipranks.comTalphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of NiyadMarch 31, 2025 | msn.comTalphera, Inc. (TLPH) Q4 2024 Earnings Call TranscriptMarch 31, 2025 | seekingalpha.comTalphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 31, 2025 | prnewswire.comTalphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 MillionMarch 31, 2025 | prnewswire.com7TLPH : Earnings Outlook For TalpheraMarch 28, 2025 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAOXG, IMUC, TLPH, and DWTX Company DescriptionsAoxing Pharmaceutical OTCMKTS:AOXG$0.0066 +0.00 (+1.54%) As of 07/16/2025 03:07 PM EasternAoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. The company's principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering body, and promoting blood circulation to remove meridian obstruction, as well as Tilidine hydrochloride, an orally-absorbed synthetic narcotic analgesic tablet used in 50mg or 100mg dosage for relief of acute, moderate to severe pain, and chronic cancer-related pain. Its products under development comprise Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone, a sublingual combo tablet that has completed Phase II clinical trials for the treatment of opioid dependence; and Tilidine/Naloxone, a compound capsule which is in Phase II clinical trial to treat acute and chronic pain. The company was formerly known as China Aoxing Pharmaceutical Company, Inc. and changed its name to Aoxing Pharmaceutical Company, Inc. in March 2010. Aoxing Pharmaceutical Company, Inc. is headquartered in Shijiazhuang, China.Dogwood Therapeutics NASDAQ:DWTX$4.76 +0.26 (+5.78%) Closing price 04:00 PM EasternExtended Trading$4.79 +0.03 (+0.63%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.EOM Pharmaceutical OTCMKTS:IMUC$0.08 0.00 (0.00%) As of 07/16/2025Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.Talphera NASDAQ:TLPH$0.43 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$0.42 -0.01 (-3.02%) As of 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Is Amazon Really the Best Forever Stock for Your Portfolio? Qualcomm: Undervalued Chip Stock in Breakout Uptrend Broadcom’s Takes on NVIDIA: Why Tomahawk Ultra Could Boost Shares CrowdStrike Bulls Beware: This Trade May Be Getting Crowded AMD Just Triggered a Signal Traders Can’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
